tbuckley/cabot-search huggingface dataset:
Abstract 9099: Echocardiographic Score versus Conventional Clinical Risk Score to Predict Thromboembolic Events at Younger Ages or First Thromboembolic Events in Patients with Non-valvular Atrial Fibrillation in Japan: The Fushimi AF Registry
Authors: Yuji Tezuka, KOSUKE DOI, Yasuhiro Hamatani, MITSURU ISHII, Moritake Iguchi, Nobutoyo Masunaga, Masahiro Esato, Hiromichi Wada, Koji Hasegawa, Hisashi Ogawa, Mitsuru Abe, Masaharu Akao
Journal: Circulation (2021)

Introduction: In patients with atrial fibrillation (AF), age and history of stroke are the strongest risk factors of thromboembolism events (TE). However, in patients with AF, especially in those with younger age or without previous TEs, preventing TEs is of clinical importance. We reported that echocardiographic (Echo) parameters such as enlarged left atrial diameter (LAD) or increased relative wall thickness (RWT) of left ventricle (LV) or smaller LV end-diastolic diameter (LVDd) were associated with incidence of TEs. We assessed whether the score based on Echo parameters (Echo score) can discriminate TEs, and compared its performance with a conventional clinical risk score. Methods: In the Fushimi AF Registry, follow-up data were available for 4,472 patients. Of them, Echo data at enrollment were available for 3,246 patients with non-valvular AF (NVAF). We investigated the relationship between Echo score [RWT ≥0.409, LVDd &lt;50 mm, LAD &gt;45 mm, each 1 point] and incidence of ischemic stroke (IS)/systemic embolism (SE) during 3 year follow-up in all patients, and patients with younger age and without previous stroke/SE, respectively. Results: During the median follow-up period of 1,095 days, 149 IS/SE events occurred. The incidence of IS/SE according to the groups stratified by Echo score is shown (Figure). Even in those with younger age or without previous stroke/SE, Echo score nicely discriminated the risk of TEs and the c-statistic was higher than that of CHA 2 DS 2 -VASc score (Table). Conclusions: Echo score better discriminated TEs in NVAF patients even with younger age or without previous TEs, than CHA 2 DS 2 -VASc score. Further research is needed to generalize the result.
Regression of Tumor Thrombus in the Suprahepatic Vena Cava of Hepatocellular Carcinoma and Conversion Hepatectomy Induced by Lenvatinib
Authors: Ryota Matsuki, Naohiro Okano, Takaaki Arai, Shinya Yoshiike, Masaharu Kogure, Yutaka Suzuki, Junji Shibahara, Junji Furuse, Yoshihiro Sakamoto
Journal: Liver Cancer (2021)

Abstract Recent developments in systemic chemotherapy for advanced hepatocellular carcinoma have been outstanding. However, reports on conversion surgery after lenvatinib therapy are scarce. We present the first case of advanced hepatocellular carcinoma with tumor thrombus in the suprahepatic vena cava close to the right atrium, which shrank after 12 weeks’ administration of lenvatinib, thereby leading to successful conversion surgery without using total vascular exclusion or extracorporeal circulation. The treatment strategy for hepatocellular carcinoma with macroscopic hepatic vein tumor thrombus is controversial, however, from a Japanese nationwide survey, surgical resection has been accepted as one of the treatment options for advanced hepatocellular carcinoma with hepatic vein tumor thrombus in Japan. However, the survival rate after resection of hepatocellular carcinoma having inferior vena cava tumor thrombus with extracorporeal circulation was reported to be worse than without extracorporeal circulation, and some preoperative down-sizing therapy for inferior vena cava tumor thrombus was advocated. Preoperative lenvatinib therapy might be a promising option among the multidisciplinary treatments for hepatocellular carcinoma with macroscopic tumor thrombus in the hepatic veins.
Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)
Authors: Wenqiang Yan, Huishou Fan, Jingyu Xu, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An
Journal: Blood (2021)
Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study
Authors: Lijun Yao, Tianjiao Wang, Sato Kazuhiro, Reyka G Jayasinghe, William Pilcher, Edgar Gonzalez-Kozlova, Yered Pita-Juarez, Taxiarchis Kourelis, Deon Doxie, Beena E Thomas, Brian Lee, Swati S Bhasin, Bhaskar Upadhyaya, Mark A Fiala, Julie Fortier, Travis Dawson, John Leech, Shaji Kumar, Hearn Jay Cho, Seunghee Kim-Schulze, Bee Raj, Stephen T. Oh, John F. DiPersio, Ravi Vij, Adeeb H Rahman, Ioannis Vlachos, Shaadi Mehr, Mark Hamilton, Daniel Auclair, Surendra Dasari, David Avigan, Madhav V Dhodapkar, Sacha Gnjatic, Manoj Bhasin, Li Ding
Journal: Blood (2021)
Mental and sexual well-being in non-binary and genderqueer individuals
Authors: Mathilde Kennis, Felix Duecker, Guy T’Sjoen, Alexander T. Sack, Marieke Dewitte
Journal: International Journal of Transgender Health (2021)

Non-binary and genderqueer (NBGQ) individuals do not identify with a binary gender identity. Some but not all NBGQ individuals identify as transgender, and it is currently unclear on which aspects of mental and sexual well-being NBGQ and binary transgender individuals may differ.
Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)
Authors: Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose Pérez-Simón, Rosa Coll, Montserrat Arnan Sangerman, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Sonia Gutierrez, Carlos Buesa, Francesc Bosch, Pau Montesinos
Journal: Blood (2021)
Cerebral Venous Thrombosis and Myeloproliferative Neoplasms: A Three-Center Study of 74 Consecutive Cases
Authors: Naseema Gangat, Paola Guglielmelli, Silvia Betti, Faiqa Farrukh, Alessandra Carobbio, Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano, Ayalew Tefferi
Journal: Blood (2021)
Devimistat in Combination with Bendamustine Potently Inhibits Tumor Growth and Promotes CD8+ T Cell Tumor Infiltration in a Syngeneic Mouse Model of CD30+ T-Cell Lymphoma
Authors: Enzo Palma, Ashley Ballard, Elizabeth Forbes, Rakhee Vaidya, Bayard L. Powell, Qianqian Song, Wei Zhang, Timothy S. Pardee
Journal: Blood (2021)
Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials
Authors: Aleksandr Lazaryan, Corey Cutler, Zhongming Yang, Jonathan Ieyoub, David Eiznhamer, Bruce R. Blazar, Stephanie J. Lee, Steven Z. Pavletic
Journal: Blood (2021)
Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma
Authors: Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei R Shustov, Brian G. Till, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Hongyan Du, Jacquelin Vandermeer, Heather A. Rasmussen, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Jason Lukas, Paul S. Martin, Edmond A Marzbani, Jenna Voutsinas, Ajay K Gopal
Journal: Blood (2021)
Abstract 12615: Slow and Oscillatory Blood-Flow in the Left Atrial Appendage is Associated With Stroke Risk in Atrial Fibrillation Patients
Authors: Nikhil Paliwal, Yuncong Mao, David D Spragg, Hugh G Calkins, Hwan-Cheol Park, Natalia Trayanova
Journal: Circulation (2021)

Introduction: Atrial fibrillation (AF) patients are at high risk of stroke with ~90% clots originating from the left atrial appendage (LAA). Studies correlating left atrial (LA) and LAA geometrical parameters with stroke exhibit conflicting results. Also, blood-flow based parameters and their association with stroke for AF patients remains unexplored. Hypothesis: Low blood-flow in the LA/LAA is associated with stroke for AF patients. Methods: We retrospectively collected CT images of 53 AF patients and dichotomized them based on clinical event into stroke and non-stroke groups. After image segmentation to obtain 3D LA geometry, personalized blood-flow analysis was performed to model LA hemodynamics. For geometry, we calculated area of 4 pulmonary veins (PVs) and area and volume of LA/LAA. For hemodynamics, we quantified blood flow velocity, wall shear stress (WSS, blood-friction on LA wall), oscillatory shear index (OSI, directional change of WSS) and endothelial cell activation potential (ECAP, ratio of OSI and WSS quantifying slow and oscillatory flow) in LA/LAA. All parameters were compared between the groups. Results: Twenty-seven patients were included in the stroke and 26 in the non-stroke group. Geometrically, there was non-significant difference between the LA/LAA area and volume, and area of PVs between the groups (Figure A). In terms of blood-flow (Figure B), velocity, WSS, OSI and ECAP in the LA had non-significant differences between the groups. However, stroke group had significantly lower velocity, WSS and higher ECAP in LAA as compared to non-stroke group. This suggests that stroke patients had slow and oscillatory circulating blood-flow in the LAA, exposing it to thrombogenesis, potentially causing stroke. Conclusion: Slow and oscillatory flow in the LAA alone is associated with stroke in this AF cohort. Personalized blood-flow analysis can identify such hemodynamic conditions, aiding in clinical stroke risk stratification of AF patients.
Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab
Authors: Nadine Abdallah, David L Murray, Angela Dispenzieri, Prashant Kapoor, Morie A. Gertz, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Wilson I Gonsalves, Eli Muchtar, Nelson Leung, David Dingli, Taxiarchis Kourelis, Rahma M Warsame, Moritz Binder, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood (2021)
Single HLA Class I Mismatches with High Peptide Divergence in the Graft-Versus-Host Direction Are Associated with Inferior Survival after 9/10 HLA-Matched UD-HCT: A Retrospective Study from the CIBMTR
Authors: Pietro Crivello, Esteban Arrieta-Bolanos, Meilun He, Tao Wang, Shahinaz M. Gadalla, Sophie Paczesny, Steven G.E. Marsh, Stephanie J. Lee, Stephen R. Spellman, Yung-Tsi Bolon, Katharina Fleischhauer
Journal: Blood (2021)
Richter's Transformation after CD-19 Directed CAR-T Cells for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Authors: Amanda Blackmon, Alexey V. Danilov, Lili Wang, Raju Pillai, Hormoz Babaei Mirshkarlo, Steven T. Rosen, Tanya Siddiqi
Journal: Blood (2021)
Homicides of American Indians/Alaska Natives — National Violent Death Reporting System, United States, 2003–2018
Authors: Emiko Petrosky, Laura M. Mercer Kollar, Megan C. Kearns, Sharon G. Smith, Carter J. Betz, Katherine A. Fowler, Delight E. Satter
Journal: MMWR Surveillance Summaries (2021)

According to the National Violent Death Reporting System, homicide is a leading cause of death for American Indians/Alaska Natives. Intimate partner violence contributes to many of these deaths, particularly among females.
Preclinical Assessment of CDR101 - a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy
Authors: Melissa Vrohlings, Jan Müller, Stephanie Jungmichel, David Senn, Anna Bianca Howald, Thomas Schleier, Fabian Scheifele, Severin Wendelspiess, Philipp Richle, Hannes Merten, Daniel Lenherr-Frey, Christian Leisner, Markus G Manz, Leonardo J. Borras
Journal: Blood (2021)
Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)
Authors: Claire Roddie, Juliana Dias, Maeve A O'Reilly, Amaia Cadinanos Garai, Louisa Green, Mahnaz Abbasian, Marina Mitsikakou, Mhairi Vaughan, Vitoria Meyer Cantinho Pereira, Maria A V Marzolini, Leigh Wood, Joanna Olejnik, Yenting Ngai, Bilyana Popova, William Wilson, Victoria Spanswick, Helen Lowe, Leah Ensell, John A. Hartley, Farzin Farzaneh, Mark W. Lowdell, David C. Linch, Martin Pule, Karl S Peggs
Journal: Blood (2021)
Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection
Authors: Henry Daniell, Smruti K. Nair, Nardana Esmaeili, Geetanjali Wakade, Naila Shahid, Prem Kumar Ganesan, Md Reyazul Islam, Ariel Shepley-McTaggart, Sheng Feng, Ebony N. Gary, Ali R. Ali, Manunya Nuth, Selene Nunez Cruz, Jevon Graham-Wooten, Stephen J. Streatfield, Ruben Montoya-Lopez, Paul Kaznica, Margaret Mawson, Brian J. Green, Robert Ricciardi, Michael Milone, Ronald N. Harty, Ping Wang, David B. Weiner, Kenneth B. Margulies, Ronald G. Collman
Journal: Molecular Therapy (2021)

To advance a novel concept of debulking virus in the oral cavity, the primary site of viral replication, virus-trapping proteins CTB-ACE2 were expressed in chloroplasts and clinical-grade plant material was developed to meet FDA requirements. Chewing gum (2 g) containing plant cells expressed CTB-ACE2 up to 17.2 mg ACE2/g dry weight (11.7% leaf protein), have physical characteristics and taste/flavor like conventional gums, and no protein was lost during gum compression. CTB-ACE2 gum efficiently (>95%) inhibited entry of lentivirus spike or VSV-spike pseudovirus into Vero/CHO cells when quantified by luciferase or red fluorescence. Incubation of CTB-ACE2 microparticles reduced SARS-CoV-2 virus count in COVID-19 swab/saliva samples by >95% when evaluated by microbubbles (femtomolar concentration) or qPCR, demonstrating both virus trapping and blocking of cellular entry. COVID-19 saliva samples showed low or undetectable ACE2 activity when compared with healthy individuals (2,582 versus 50,126 ΔRFU; 27 versus 225 enzyme units), confirming greater susceptibility of infected patients for viral entry. CTB-ACE2 activity was completely inhibited by pre-incubation with SARS-CoV-2 receptor-binding domain, offering an explanation for reduced saliva ACE2 activity among COVID-19 patients. Chewing gum with virus-trapping proteins offers a general affordable strategy to protect patients from most oral virus re-infections through debulking or minimizing transmission to others.
STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery
Authors: Ginimol Mathew, Riaz Agha, Joerg Albrecht, Prabudh Goel, Indraneil Mukherjee, Prathamesh Pai, Anil K. D’Cruz, Iain J. Nixon, Klappenbach Roberto, Syed Ather Enam, Somprakas Basu, Oliver J. Muensterer, Salvatore Giordano, Duilio Pagano, David Machado-Aranda, Patrick James Bradley, Mohammad Bashashati, Achilles Thoma, Raafat Y. Afifi, Maximilian Johnston, Ben Challacombe, James Chi-Yong Ngu, Mushtaq Chalkoo, Kandiah Raveendran, Jerome R. Hoffman, Boris Kirshtein, Wan Yee Lau, Mangesh A. Thorat, Diana Miguel, Andrew James Beamish, Gaurav Roy, Donagh Healy, Hammad M Ather, Shahzad G. Raja, Zubing Mei, Todd G. Manning, Veeru Kasivisvanathan, Juan Gómez Rivas, Roberto Coppola, Burcin Ekser, Veena L. Karanth, Huseyin Kadioglu, Michele Valmasoni, Ashraf Noureldin
Journal: International Journal of Surgery (2021)
Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)
Authors: Nancy L. Bartlett, Christopher A. Yasenchak, Khaleel Ashraf, William Harwin, Robert Sims, Grzegorz S. Nowakowski
Journal: Blood (2021)
Abstract 9296: Impact of the Covid Pandemic on Aortic Valve Replacement and Coronary Artery Bypass Graft Surgical Outcomes
Authors: Daniel Fox, Karen Joynt Maddox
Journal: Circulation (2021)

Introduction: Patients with coronary artery disease or cardiac valvular disease in need of cardiac surgery are typically high-risk, and may have been impacted either by delays in seeking care for their underlying cardiac condition, or by disruptions in hospital care itself. Hypothesis: we examined changes in volume, complexity, and outcomes for aortic valve replacement (AVR) and coronary artery bypass graft (CABG) patients at a large midwestern teaching hospital during the COVID pandemic. Methods: We used diagnosis and procedure codes to identify all patients undergoing AVR or CABG, without a documented COVID19 diagnosis, at Barnes-Jewish Hospital between 1/2018 and 9/2020. We used multivariable regression models to examine the association between the COVID time period and outcomes, controlling for age, sex, and medical comorbidities. Results: For the AVR and CABG cohort, we saw no statistically significant differences in weekly volume, age, gender, payor, or race (Table 1).In the AVR cohort, patients were more complex during COVID, and risk-adjusted in-hospital mortality was higher during COVID compared to pre-COVID. For the CABG cohort, we found numeric increases but no statistically significant differences in patient complexity, nor in risk-adjusted mortality (Figure 1). Conclusions: We found higher in-hospital mortality among patients undergoing AVR during COVID, a pattern that was not statistically significant in CABG. These findings suggest that outreach to patients is critical to ascertain which patients require necessary surgical care during future pandemic waves or other disruptions to usual care.
Renal Manifestations and Their Association with Mortality in COVID-19 Patients at a Safety-Net Hospital
Authors: Sandra Gomez Paz, Eric Lam, Luis Gonzalez Mosquera, Diana Cardenas-Maldonado, Joshua Fogel, Sofia Rubinstein
Journal: Journal of the American Society of Nephrology (2021)

Background: Renal involvement in COVID-19 leads to severe disease and higher mortality. We study additional previously not studied renal parameters in COVID-19 patients and their association with mortality. Methods: A retrospective study (n=340) of confirmed COVID-19 patients with renal involvement determined by the presence of acute kidney injury. Multivariate analyses of logistic regression for mortality and linear regression for length of stay (LOS) adjusted for relevant demographic, comorbidity, disease severity, and treatment covariates. Results: Mortality was 54.4% and mean LOS was 12.9 days. For mortality, creatinine peak (OR:35.27, 95% CI:2.81, 442.06, p<0.01) and persistent renal involvement at discharge (OR:4.47, 95% CI:1.99,10.06, p<0.001) were each significantly associated with increased odds for mortality. Increased blood urea nitrogen peak (OR:0.98, 95%CI:0.97,0.996, p<0.05) was significantly associated with decreased odds for mortality. For LOS, increased blood urea nitrogen peak (B:0.001, SE:<0.001, p<0.01), renal replacement therapy (B:0.19, SE:0.06, p<0.01), and increased days to acute kidney injury (B:0.19, SE:0.05, p<0.001) were each significantly associated with increased length of stay. Conclusions: As persistent renal involvement at discharge is associated with increased odds for mortality, this suggests that early identification of renal involvement characteristics in COVID-19 patients is useful for treatment management. Clinicians should focus on renal parameters of blood urea nitrogen peak, renal replacement therapy, and days to acute kidney injury for predicting patient length of stay.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
Authors: Jean Galtier, Camille Alric, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Audrey Bidet, Eric Delabesse, Jean Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Anne-Charlotte de Grande, Audrey Sarry, Arnaud Pigneux, Christian Récher, Sarah Bertoli, Pierre-Yves Dumas
Journal: Blood Cancer Journal (2021)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline
Circulating Metabolites and the Development of Type 2 Diabetes in Chinese Adults
Authors: Fiona Bragg, Christiana Kartsonaki, Yu Guo, Michael Holmes, Huaidong Du, Canqing Yu, Pei Pei, Ling Yang, Donghui Jin, Yiping Chen, Dan Schmidt, Daniel Avery, Jun Lv, Junshi Chen, Robert Clarke, Michael Hill, Liming Li, Iona Millwood, Zhengming Chen
Journal: Diabetes Care (2021)

OBJECTIVE To assess prospective associations of circulating metabolites with the risk of type 2 diabetes (T2D) among Chinese adults. RESEARCH DESIGN AND METHODS A case-cohort study within the 8-year prospective China Kadoorie Biobank comprised 882 participants with incident T2D and 789 subcohort participants. Nuclear magnetic resonance metabolomic profiling quantified 225 metabolites in stored baseline plasma samples. Cox regression related individual metabolites with T2D risk, adjusting for potential confounders and fasting time. RESULTS After correction for multiple testing, 163 metabolites were significantly associated with the risk of T2D (P &amp;lt; 0.05). There were strong positive associations of VLDL particle size, the ratio of apolipoprotein B to apolipoprotein A-1, branched-chain amino acids, glucose, and triglycerides with T2D, and inverse associations of HDL-cholesterol, HDL particle size, and relative n-3 and saturated fatty acid concentrations. CONCLUSIONS In Chinese adults, metabolites across diverse pathways were independently associated with T2D risk, providing valuable etiological insights and potential to improve T2D risk prediction.
Abstract 19809: Interferon Regulatory Factor 2 Binding Protein 2 Inhibits Macrophage Inflammation and Reduces Susceptibility to Atherosclerosis in Mice and Humans
Authors: Ragnar O Vilmundarson, Hsiao-Huei Chen, Kianoosh Keyhanian, Xun Zhou, Majid Nikpay, Shelly A Cruz, Nihar R Pandey, Naif A Almontashiri, Nida L Yap, Tiffany Ho, Chloe A Stewart, Hua Huang, Aswin Hari, Michele Geoffrion, Ruth McPherson, Katey J Rayner, Alexandre F Stewart
Journal: Circulation (2015)

Introduction: Genetic variants near the gene encoding the transcription cofactor Interferon Regulatory Factor 2 Binding Protein 2 (IRF2BP2) have been tied to ischemic heart disease progression and elevated serum cholesterol. Expression of IRF2BP2 is suppressed in inflammatory macrophages, but the significance of this down-regulation was not known. Hypothesis: This study sought to determine the function of IRF2BP2 in macrophages and its effect on atherosclerosis in mice and humans. Methods and Results: We generated mice that delete IRF2BP2 in macrophages (LysMCre/IRF2BP2flox). IRF2BP2-deficient macrophages increased atherosclerosis in irradiated LDL-receptor null recipient mice and in ApoE null mice. Atherosclerosis was associated with a skewed inflammatory macrophage polarization and increased foam cell formation. Microarray analysis revealed and promoter studies confirmed that the anti-inflammatory transcription factor KLF2 is a target of IRF2BP2, indicating an important role for IRF2BP2 in macrophage polarization. A deletion polymorphism (rs3045215) in the 3’ untranslated sequence of human IRF2BP2 mRNA was examined for its effect on protein expression and on the susceptibility to coronary artery disease (CAD) risk in a cohort of 1,066 angiographic cases and 1,011 controls. Homozygous carriers of this deletion had lower IRF2BP2 (and its target KLF2) protein levels in peripheral blood mononuclear cells and a higher risk of CAD (recessive model, odds ratio (95%CI) = 1.560 (1.179-2.065), p=1.73E-03). The effect of this deletion to suppress protein expression was confirmed with luciferase reporter studies. Haplotype phasing identified two surrogate SNPs in modest LD (rs1887917, r2= 0.755 and rs632180, r2=0.614) that also associated with CAD in a recessive model. These SNPs are being tested for association with CAD in a large international consortium. Conclusion: Ablation of IRF2BP2 in macrophages worsens atherosclerosis in mice and a deletion variant that lowers IRF2BP2 expression predisposes to CAD in humans.